Insulin glargine vs NPH insulin
Serious adverse events (n/N)
Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
1 finding from 1 review
- (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes onlyRR 1.08 [0.63, 1.84]8 studies · 2229 participantsModerate